|Bid||12.65 x 1100|
|Ask||26.00 x 800|
|Day's Range||12.40 - 13.30|
|52 Week Range||11.00 - 26.74|
|Beta (3Y Monthly)||0.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit a 52-week peak Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 27) • Aevi ...
Does Merus N.V. (NASDAQ:MRUS) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]
Merus NV (NASDAQ:MRUS), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is MRUS will Read More...
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN), which was later amended in February 2017. As per the amended agreement, the ongoing research programs for the development of checkpoint modulator antibodies targeted at GITR and OX40 have been converted from co-funded ones to being fully funded by Incyte. Additionally, the profit-sharing arrangement for these research programs has been converted into royalty-bearing programs.